A decrease in cell viability and cell proliferation as well as an increase in apoptosis and cell cycle arrest have been demonstrated in both AML and NHL cell lines treated with PRMT5 inhibitors [18,76,79,80,82,83,110,113,114,119]. Here, PRMT5 is linked to non-Hodgkin lymphoma.